Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine
- 542 Downloads
The cholinergic system is involved in cognition as well as in age-related cognitive decline and Alzheimer disease (AD). Cholinergic enhancers ameliorate AD symptoms and represent the main current therapy for AD. MTC (Methylthioninium chloride), an antioxidant with metabolism-enhancing properties may be a novel candidate with pro-cognitive capacities.
This study was performed: (1) to assess the pro-cognitive efficacy of MTC and establish its dose-response; (2) to compare the efficacy of MTC with rivastigmine and (3) to determine the potential for combination therapy by co-administration of MTC and rivastigmine.
Spatial cognition of female NMRI mice was tested in a reference memory water maze task. Subjects received intra-peritoneal injections of scopolamine (0.5 mg/kg) followed by vehicle, and/or MTC and/or rivastigmine (0.15–4 mg/kg MTC; 0.1–0.5 mg/kg rivastigmine) in mono or combination treatment.
Scopolamine treatment prevented spatial learning in NMRI female mice and the deficit was reversed by both rivastigmine and MTC in a dose-dependent manner. Mono-therapy with high doses of rivastigmine (>0.5 mg/kg) caused severe side effects but MTC was safe up to 4 mg/kg. Co-administration of sub-effective doses of both drugs acted synergistically in reversing learning deficits and scopolamine-induced memory impairments.
In our model, MTC reversed the spatial learning impairment. When combined with the ChEI rivastigmine, the effect of MTC appeared to be amplified indicating that combination therapy could potentially improve not only symptoms but also contribute beneficially to neuronal metabolism by minimising side effects at lower doses.
KeywordsMethylthioninium chloride Methylene blue Rivastigmine Scopolamine Water maze Amnesia Combination study Synergy Acetylcholine receptor Spatial learning NMRI mouse Cognitive enhancer
This work was supported by TauRx Therapeutics Ltd., Singapore.
- Birks J (2006) Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database of Systematic Reviews Issue 1, Article No. CD005593Google Scholar
- Deutsch SI, Rosse RB, Paul SM, Tomasino V, Koetzner L, Morn CB, Mastropaolo J (1996) 7-Nitroindazole and methylene blue, inhibitors of neuronal nitric oxide synthase and NO-stimulated guanylate cyclase, block MK-801-elicited behaviors in mice. Neuropsychopharmacology 15(1):37–43PubMedCrossRefGoogle Scholar
- Lindner MD, Hogan JB, Hodges DB Jr, Orie AF, Chen P, Corsa JA, Leet JE, Gillman KW, Rose GM, Jones KM, Gribkoff VK (2006) Donepezil primarily attenuates scopolamine-induced deficits in psychomotor function, with moderate effects on simple conditioning and attention, and small effects on working memory and spatial mapping. Psychopharmacology (Berl) 188(4):629–640CrossRefGoogle Scholar
- Martinez JL Jr, Jensen RA, Vasquez BJ, McGuinness T, McGaugh JL (1978) Methylene blue alters retention of inhibitory avoidance responses. Physiol Psychol 6:387–390Google Scholar
- Milivojevic N, Babic K, Milatovic D, Dettbarn WD, Sket D, Zivin M (2001) N-tert-butyl-alpha-phenylnitrone, a free radical scavenger with anticholinesterase activity does not improve the cognitive performance of scopolamine-challenged rats. Int J Dev Neurosci 19(3):319–325PubMedCrossRefGoogle Scholar
- Ostrovskaya RU, Gruden MA, Bobkova NA, Sewell RD, Gudasheva TA, Samokhin AN, Seredinin SB, Noppe W, Sherstnev VV, Morozova-Roche LA (2007) The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer’s disease model. J Psychopharmacol 21(6):611–619PubMedCrossRefGoogle Scholar
- Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, Lavretsky H, Miller K, Siddarth P, Rasgon NL, Mazziotta JC, Saxena S, Wu HM, Mega MS, Cummings JL, Saunders AM, Pericak-Vance MA, Roses AD, Barrio JR, Phelps ME (2000) Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease. Proc Natl Acad Sci 97:6037–6042PubMedCrossRefGoogle Scholar